REGENXBIO Schedules September Investor Presentations in New York
REGENXBIO Inc. executives will headline a pair of investor fireside chats in New York this September to outline progress on their gene therapy pipeline. The Rockville-based firm aims to maintain market visibility as it advances late-stage clinical programs for rare and retinal diseases throughout the coming year.
The company’s leadership team is set to present at the Baird 2026 Global Healthcare Conference on September 15, followed by a session at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. Both events begin at 8:30 a.m. ET, with live webcasts available via the firm's investor relations portal. Replays will remain accessible for 30 days post-conference.
Since its 2009 founding, the company has focused on AAV gene therapy development. Current late-stage efforts include RGX-202 for Duchenne muscular dystrophy, and the ongoing partnership with Nippon Shinyaku for RGX-121 and RGX-111. Additionally, the firm continues its collaboration with AbbVie on surabgene lomparvovec, targeting wet AMD and diabetic retinopathy.
Comments (0)
No comments yet. Be the first!